Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Zilebesiran

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Chugai in-licenses RNAi therapeutic zilebesiran for hyp.high cardiovascular risk
    Chugai in-licenses RNAi therapeutic zilebesiran for hyp.high cardiovascular risk

    20 Apr 2024

    // PHARMABIZ

    https://www.pharmabiz.com/NewsDetails.aspx?aid=168662&sid=2

    PHARMABIZ
    20 Apr 2024
    Share Share
    Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran
    Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran

    07 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240407631982/en

    BUSINESSWIRE
    07 Apr 2024
    Share Share
    Alnylam to Webcast to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran
    Alnylam to Webcast to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran

    20 Mar 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240320967622/en

    BUSINESSWIRE
    20 Mar 2024
    Share Share
    Roche, Alnylam say blood pressure drug succeeds in mid-stage trial
    Roche, Alnylam say blood pressure drug succeeds in mid-stage trial

    06 Mar 2024

    // BIOPHARMA DIVE

    https://www.biopharmadive.com/news/alnylam-roche-hypertension-drug-study-results-zilebesiran/709303/

    BIOPHARMA DIVE
    06 Mar 2024
    Share Share
    Alnylam Reports Positive Results from Phase 2 Dose-Ranging Study of Zilebesiran
    Alnylam Reports Positive Results from Phase 2 Dose-Ranging Study of Zilebesiran

    07 Sep 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230907817269/en

    BUSINESSWIRE
    07 Sep 2023
    Share Share
    Roche enters partnership with Alnylam for hypertension therapy
    Roche enters partnership with Alnylam for hypertension therapy

    25 Jul 2023

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/roche-enters-partnership-with-alnylam-hypertension-therapy-2023-07-24/

    REUTERS
    25 Jul 2023
    Share Share